Popular Articles
Teeth Whitening

Common Autism Medication Is Ineffective For Repetitive Behaviors, Study Finds
June 1, 2009: Citalopram (Celexa), a medication commonly prescribed to children with autism spectrum disorders (ASD), was no more effective than a placebo at reducing repetitive behaviors, according to a multi-site clinical trial guided by lead author Bryan H. King, MD, director of child and adolescent psychiatry at Seattle Children"s Hospital and professor and vice chair of psychiatry at the University of Washington School of Medicine. Because citalopram is also prescribed for patients with obsessive compulsive disorders (OCD), these study results may challenge the widely held premise that repetitive behaviors in children with ASD are similar to repetitive behaviors often found in cases of OCD. The study "Lack of Efficacy of Citalopram in Children with Autism Spectrum Disorders and High Levels of Repetitive Behavior" was published in the June 2009 issue of Archives of General Psychiatry.
generic viagra online
New THT Campaign Tells Younger Gay Men The Facts About Sexual Health Clinics, UK
Terrence Higgins Trust (THT) is launching a new campaign to reduce levels of undiagnosed HIV by encouraging gay men, and particularly younger gay men, to start regularly attending sexual health clinics. The campaign will use a stand-alone website (http://www.betterclinics.co.uk), media adverts, posters, condom packs and pin badges to dispel some of the myths about clinics and what the testing process involves.
News of the day
Cook Medical And LMA Urology Ltd Forge Global Partnership To Advance Global Treatment Of Stone Disease
Cook Medical and LMA Urology Ltd have entered into a strategic partnership that can significantly improve the remedies available for stone disease management. Through the worldwide agreement, Cook will market and distribute LMA"s StoneBreakerTM, a portable pneumatic lithotripter for stone fragmentation.
Sexual Health

Upcoming BioAlliance Pharma's Presentations At International Conferences On Infectious Diseases And Oncology

BioAlliance Pharma SA (Paris:BIO), a company dedicated to therapies and supportive care for cancer and AIDS patients, announced its scientific communications at upcoming international conferences on infectious diseases and oncology: Loramyc®, indicated for fungal infections in immune-compromised patients with HIV or cancer The 2009 American Society of Clinical Oncology (ASCO) Annual Meeting May 29 to June 2, 2009 - Orlando, Florida, USA. Abstract: "Prevalence and management of oropharyngeal candidiasis (OPC) by medical and radiation oncologists in cancer patients". At the American Conference for the Treatment of HIV (ACTHIV) that took place on May 15-17, 2009 in Denver, Colorado, USA, BioAlliance Pharma presented the poster: "Once-Daily Miconazole Mucoadhesive Buccal Tablet is an Effective and Safe Treatment for Oropharyngeal Candidiasis". Amep™, a biotherapy for Metastatic Melanoma treatment American Society of Gene Therapy (ASGT) 12th Annual Meeting May 27-30, 2009 - San Diego, California, USA Poster: "Complete Melanoma Regressions after Electrotransfer of the p-AMEP™ Plasmid Coding for an Anti-Angiogenic and Anti-Metastatic Peptide", May 28. Anti-integrases: new antiretroviral drugs for the treatment of resistant HIV-1 XVIII International HIV Drug Resistance Workshop June 9-13, 2009 - Fort Myers, Florida, USA Oral communication and poster: "New integrase binding inhibitors acting in synergy with Raltegravir", June 12. Irinotecan SRN oral formulation for the treatment of advanced colorectal cancer 2nd Pharmaceutical Sciences Fair and Exhibition (PharmSciFair) June 8-12, 2009, Nice, France Oral communication: "Sustained Release Nanoparticles (SRN) for oral administration of Irinotecan", June 10. BioAlliance Pharma


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):